Menu
Search
|

Menu

Close
X

Athenex Inc ATNX.OQ (NASDAQ Stock Exchange Global Select Market)

14.42 USD
+0.79 (+5.80%)
As of 12:22 PM EDT
Previous Close 13.63
Open 13.81
Volume 143,438
3m Avg Volume 240,402
Today’s High 14.70
Today’s Low 13.81
52 Week High 21.11
52 Week Low 9.38
Shares Outstanding (mil) 77.07
Market Capitalization (mil) 1,412.61
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
25
FY18
89
FY17
38
FY16
21
EPS (USD)
FY19
-0.526
FY18
-1.801
FY17
-1.930
FY16
-1.512
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
18.45
7.90
Price to Book (MRQ)
vs sector
11.47
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
44.54
17.64
LT Debt to Equity (MRQ)
vs sector
42.94
12.61
Return on Investment (TTM)
vs sector
-97.17
12.69
Return on Equity (TTM)
vs sector
-110.72
17.13

EXECUTIVE LEADERSHIP

Johnson Lau
Chief Executive Officer and Chairman of the Board, Since 2011
Salary: $500,000.00
Bonus: --
Randoll Sze
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
William Zuo
President, Polymed Therapeutic, Since 1995
Salary: --
Bonus: --
Jeffrey Yordon
Chief Operating Officer and President, Athenex Pharmaceutical Division, Since 2017
Salary: $400,000.00
Bonus: --
Rudolf Kwan
Chief Medical Officer, Since 2014
Salary: $314,615.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1001 Main St Ste 600
BUFFALO   NY   14203-1009

Phone: +1716.8988625

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.

SPONSORED STORIES